Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single centre retrospective study of Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141

Next Previous
Trial Profile

A single centre retrospective study of Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Adenoma; Adenosquamous carcinoma; Bone cancer; Carcinoma; Eye neoplasms; Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Neuroblastoma; Neuroendocrine carcinoma; Oropharyngeal cancer; Salivary gland cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 01 Jul 2022 Retrospective analysis data(n=59) showing comparable efficacy of Nivolumab for cancers involving the salivary gland/nasopharynx and non-SCC histology to that in CheckMate 141 study published in the Oral Oncology.
  • 29 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top